A new study, published in the journal Nature, estimates how advanced Ebola virus disease may be reverted with the use of an experimental drug. The researchers modeled the spread and control of Ebola using non-human primates. The experimental drug was a combination of monoclonal antibodies, known as ZMapp. In particular, ZMapp showed a higher efficacy than other therapeutics that are currently used for treating Ebola.

While promising, the one major obstacle is a lack of supply, reports The New York Times. In this study, all 18 of the monkeys that were given a lethal dose of the Ebola virus survived after being treated with ZMapp. They even survived if treatment was given five days after infection when they were already sick. In contrast, the three monkeys without treatment all died. In order to be able to implement ZMapp for combating Ebola in humans, a major increase in supply is needed.

Fortunately, U.S. laboratories are ready to begin working on Ebola drugs if asked, reports Reuters. The U.S. Department of Health and Human Services (HHS), in conjunction with private industry partners, has established three Centers for Innovation in Advanced Development and Manufacturing (ADM). ADMs were established to quickly make vaccines and therapeutics in the event of a major public health threat. These facilities could be the key to producing and distributing ZMapp, which would allow for cure of Ebola cases and control of further spread.